Microbix Schedules Release of Results for Q3 Fiscal 2026

Rhea-AI Summary

Microbix Biosystems (TSX:MBX, OTCQX:MBXBF) plans to file its financial statements, management discussion and analysis, and news release for Q3 fiscal 2026 (quarter ended June 30, 2026) before the start of trading on August 13, 2026.

On the same day at 10:00 AM ET, Microbix intends to host a results webinar featuring its CEO, CFO, and COO, moderated by Adelaide Capital, with live access via Zoom registration and YouTube, and a replay to follow. The company also highlights its 2025 revenues of C$18.6 million and its global portfolio of diagnostic ingredients, quality assessment products (QAPs, QUANTDx), and other proprietary life sciences technologies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Results Release and Webinar Discussion on Morning of August 13, 2026

MISSISSAUGA, ON / ACCESS Newswire / August 6, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF), (Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its third quarter of fiscal 2026 ended June 30, 2026 ("Q3 2026") prior to the start of trading on August 13, 2026. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q3 2026 results with its CEO, CFO, and COO.

Investors and shareholders can participate in the webinar, hosted by Adelaide Capital, by registering at: https://us02web.zoom.us/webinar/register/WN_D5IwAcS3TdeAfMjZ9peU0A. It will also be live-streamed to YouTube at: https://www.youtube.com/channel/UC7Jpt_DWjF1qSCzfKlpLMWw.

Phone one-tap:

+15873281099,,81360866914# Canada
+16473744685,,81360866914# Canada

Join via audio:

+1 587 328 1099 Canada

Webinar ID: 813 6086 6914
International numbers available: https://us02web.zoom.us/u/kdOeAkesdj
A replay of the webinar will also be made available on Adelaide Capital's YouTube channel.

About Microbix Biosystems Inc.

Microbix Biosystems Inc. creates proprietary biological products for human health, with over 120 skilled employees and revenues of C$ 18.6 million in its last reported fiscal year (2025). It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) and reference materials (QUANTDx™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs or QUANTDx are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 certified, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM™ for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada.

Forward-Looking Information

This news release includes "forward-looking information," as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, expected timing of release of financial results, intended discussion of financial results or the outlook for the business, risks associated with its financial results and stability, its current or future products, development projects such as those referenced herein, access to and sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining adequate working capital and raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management's current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking information is inherently uncertain, and that actual performance may be affected by many material factors, some of which are beyond the Company's control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company's judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information except as required by applicable law.

Please visit www.microbix.com or www.sedarplus.ca for recent Microbix news and filings.

For further information, please contact Microbix at:

Cameron Groome, CEO (905) 361-8910

Jim Currie, CFO (905) 361-8910

Deborah Honig, Investor Relations Adelaide Capital Markets (647) 203-8793 ir@microbix.com

Copyright © 2026 Microbix Biosystems Inc.

Microbix®, DxTM™, Kinlytic®, QAPs™, and QUANTDx™ are trademarks of Microbix Biosystems Inc.

SOURCE: Microbix Biosystems Inc.

View the original press release on ACCESS Newswire

FAQ

When will Microbix (MBXBF) release its Q3 2026 financial results?

Microbix expects to release its Q3 fiscal 2026 results before trading begins on August 13, 2026. According to Microbix, this includes financial statements, management discussion and analysis, and a detailed news release for the quarter ended June 30, 2026.

How can investors join the Microbix Q3 2026 results webinar on August 13, 2026?

Investors can join the Microbix Q3 2026 webinar by registering via Zoom and watching the simultaneous YouTube livestream. According to Microbix, the webinar hosted by Adelaide Capital starts at 10:00 AM ET and a replay will later be available on Adelaide Capital’s YouTube channel.

Who will present at the Microbix (MBXBF) Q3 2026 earnings webinar?

The Q3 2026 webinar will feature Microbix’s CEO, CFO, and COO discussing quarterly results. According to Microbix, Adelaide Capital will host the session, providing investors and shareholders an opportunity to hear management’s commentary and ask questions about recent financial and operational performance.

What were Microbix’s most recently reported annual revenues before Q3 2026?

Microbix reported revenues of C$18.6 million in its last reported fiscal year 2025. According to Microbix, this revenue was generated from proprietary biological products that support global diagnostic assays, including antigens, QAPs quality assessment products, and QUANTDx reference materials for clinical laboratories.

What does Microbix Biosystems (MBXBF) do in the diagnostics market?

Microbix creates proprietary biological products that enable commercialization of diagnostic assays worldwide. According to Microbix, it supplies antigens for immunoassays and quality products like QAPs and QUANTDx, supporting proficiency testing, assay development, validation, and clinical diagnostic workflow quality in more than 30 countries.

On which exchanges is Microbix traded and where is it headquartered?

Microbix shares trade on the TSX and OTCQX markets under the symbol MBXBF in the U.S. According to Microbix, the company is headquartered in Mississauga, Ontario, Canada and focuses on life sciences and diagnostic-support products.